CytoSorbents CTSO 深 滬
等待開盤 12-18 09:30:00 美东时间
0.643
+0.003
+0.47%
華盛通- 最 高0.666
- 今 開0.65
- 成交量 9.15万股
- 最 低 0.64
- 昨 收 0.64
- 總市值 4025.85万
- 52周最高 1.61
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 0.60
- 委 比 99.24%
- 總股本 6261.04万
- 歷史最高 15.24
- 量 比 0.47
- 振 幅 4.06%
- 歷史最低 0.09
- 每 手 1
- 風險率 0.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
12-17 10:46
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.
12-17 02:03
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
HC Wainwright & Co. Maintains Neutral on CytoSorbents, Lowers Price Target to $0.75
HC Wainwright & Co. analyst Sean Lee maintains CytoSorbents (NASDAQ:CTSO) with a Neutral and lowers the price target from $1 to $0.75.
11-14 21:07
CytoSorbents Q3 Adj. EPS $(0.04) Beats $(0.05) Estimate, Sales $9.485M Miss $10.034M Estimate
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 14.89 percent. This is a 50 percent increase over losses of $(0.08) per share from the
11-14 05:09
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $10 price target.
09-16 21:11
CytoSorbents To Refile De Novo Application For DrugSorb-ATR, Expects FDA Review In Mid-2026
CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today provided a regulatory update on
09-16 19:14
CytoSorbents Provides DrugSorb-ATR Regulatory Update
PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surge...
09-16 19:00
